Retatrutide is the compound researchers ask about more than any other in our catalogue, and it is also the one most often described loosely. It is a synthetic peptide that activates three receptors at once. That single fact drives its structure, its handling, and the kinds of questions a laboratory can put to it. This article lays out what the molecule is, where it came from, and what the published work actually covers.
The short definition
Retatrutide is a 39-residue lipidated synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. In the literature it is often called a GGG tri-agonist, for the three receptor families it engages. Its registry identifiers are CAS 2381089-83-2, molecular formula C256H392N64O79, and a molecular weight of 4731.2. It is supplied as a lyophilized powder and reconstituted before use.
Where the molecule came from
Retatrutide entered the literature under the development code LY3437943. It sits in a line of engineered incretin peptides that began with single-receptor GLP-1 analogs, moved to dual GLP-1 and GIP agonists, and then added glucagon receptor activity as a third arm. The design logic was published by Coskun and colleagues in 2022, which remains the reference description of the compound's receptor pharmacology. Earlier proof that a single chain could carry glucagon and GLP-1 activity together came from rodent work in the late 2000s, and that result is what made a three-receptor peptide plausible in the first place.
Why 39 residues and a fatty acid chain
The backbone is long enough to present binding surfaces for three different receptors, which a short peptide cannot do. Native incretin hormones are cleared from circulation within minutes, so the engineered versions carry a fatty diacid chain attached through a linker. That chain binds serum albumin, and albumin binding is what stretches the circulating half-life of this class into the multi-day range reported in published pharmacokinetics. The chain also makes the molecule noticeably more hydrophobic than a plain linear peptide, which matters at the bench.
The engineered ratio between the three signals
The three activities are not balanced, and the imbalance is deliberate. Published pharmacology describes relatively strong activity at the GIP receptor, intermediate activity at the GLP-1 receptor, and comparatively weaker activity at the glucagon receptor. The rationale is that glucagon receptor signaling contributes on one axis, energy expenditure and hepatic substrate handling in preclinical models, while the incretin arms counterbalance its effect on circulating glucose. Change the ratio and you change the compound, which is why retatrutide is not interchangeable with any other triple agonist in a study design.
The one-receptor and two-receptor comparators sit in the same family. Tirzepatide covers GLP-1 and GIP without the glucagon arm, which makes it the natural control when the question is what the third receptor contributes. We set the three side by side in our comparison of the incretin peptides.
What the published work models
Preclinical and published research using this compound concentrates on receptor pharmacology and energy balance in cell and rodent systems. Typical work includes receptor binding and signaling assays in engineered cell lines expressing one receptor at a time, cyclic AMP accumulation as a readout of activation, comparative studies against single- and dual-agonist peptides, and metabolic phenotyping in rodent models. Nothing in this article describes outcomes in people, and the compound is supplied here strictly as a laboratory reagent.
Vial sizes and what they give you
We stock five sizes. The table shows the concentration each reaches at two common reconstitution volumes, using label mass rather than net peptide content.
| Vial | With 1 mL diluent | With 2 mL diluent | Mass in a 0.1 mL draw at 2 mL |
|---|---|---|---|
| 10 mg | 10 mg/mL | 5 mg/mL | 500 µg |
| 20 mg | 20 mg/mL | 10 mg/mL | 1 mg |
| 30 mg | 30 mg/mL | 15 mg/mL | 1.5 mg |
| 48 mg | 48 mg/mL | 24 mg/mL | 2.4 mg |
| 60 mg | 60 mg/mL | 30 mg/mL | 3 mg |
Larger vials cost less per milligram, which is why long-running work tends to move up the range. The trade-off is that a bigger vial sits open longer once reconstituted. Our vial size guide works through that decision.
Handling a lipidated peptide
The fatty acid chain changes the practical behaviour of the powder in three ways worth knowing before the first vial is opened.
- Dissolution is slower. Add diluent down the inside wall of the vial, then swirl gently and give it several minutes. Shaking produces foam, and foam at an air-water interface is where peptide aggregation starts.
- Adsorption is real. Hydrophobic peptides stick to plastic. For low-concentration working solutions, glass or low-binding plasticware keeps more of the material in solution than standard polypropylene.
- Serum-free media behaves differently. Albumin is the compound's carrier in plasma. In a serum-free assay that partner is absent, and apparent potency can shift for reasons that have nothing to do with the receptor.
Identity is the other handling point. Several lipidated incretin peptides have similar lengths and similar retention on a reverse-phase column, so a purity number alone does not tell you which one is in the vial. Mass spectrometry does. Every lot we release carries independent HPLC purity and mass-spec identity results, and the lot-matched certificate is available on request.
The cagrilintide pairing
We also supply retatrutide with cagrilintide. Cagrilintide is not an incretin. It is a long-acting amylin analog, so the pairing adds a fourth signalling axis rather than adjusting the three already present. Labs running that combination are asking a different question, and the two components need separate bookkeeping in reconstitution records. We cover the pairing in retatrutide and cagrilintide explained.
Frequently asked questions
Is retatrutide a peptide or a small molecule?
A peptide. It is a 39-residue chain with a fatty diacid modification, not a small organic molecule. Its molecular weight of 4731.2 places it firmly in the peptide range.
Why does a glucagon receptor agonist appear in a metabolic research compound?
Glucagon receptor signaling raises hepatic glucose output on its own. In the triple agonist design its contribution is framed around energy expenditure and liver substrate handling, with the GLP-1 and GIP arms offsetting the glucose effect. The published rationale is about the combination, not the glucagon arm in isolation.
Does the powder need refrigeration before reconstitution?
Sealed lyophilized powder is stable cool, dry and away from light. Refrigeration after reconstitution is the step that matters most, along with recording the date the vial was first opened.
References
- Coskun T, et al. 2022. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism.
- Day JW, et al. 2009. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology.
- Müller TD, et al. 2019. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism.
- Campbell JE, Drucker DJ. 2015. Islet alpha cells and glucagon: critical regulators of energy homeostasis. Nature Reviews Endocrinology.
Research use only. Everything above describes laboratory and preclinical research. Homegrown Peptides products, including every item in our GLP-1 research collection, are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice.
